Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABI-007 and Carboplatin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ABI-007 and Carboplatin | EXPERIMENTAL | ABI-007 and Carboplatin in patients with Advanced Non-Small Cell Lung Cancer. |
| Name | Type | Description |
|---|---|---|
| ABI-007 (Abraxane) and Carboplatin | DRUG | ABI-007 plus Carboplatin will be administered intravenously over 30 minutes in cycles of 3 weeks |
Inclusion Criteria: * Histologically or cytologically confirmed NSCLC Stage IIIB with pleural effusion or evidence of inoperable local recurrence or metastasis (Stage IV). * Male or non-pregnant and non-lactating female, and ≥ 18 years of age. ( )If a female patient is of child-bearing potential, a...
ABI-007 is an investigational small molecule being studied for the treatment of several cancers, including breast cancer, non-small cell lung cancer, melanoma, and colorectal neoplasms. Clinical trials have evaluated it in patients with metastatic breast cancer, advanced non-small cell lung cancer, and metastatic melanoma.
ABI-007 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical research on this investigational oncology drug.
ABI-007 is in Phase 3 clinical development. It has completed Phase 1, Phase 2, and Phase 3 trials. The drug remains investigational and has not been approved by the FDA for any indication.
ABI-007 has been studied in several completed clinical trials. NCT00046514 evaluated it in taxol-resistant patients with metastatic breast cancer, NCT00046527 compared it with Taxol in metastatic breast cancer, NCT00073723 tested it in chemotherapy-naive patients with advanced non-small cell lung cancer, and NCT00093119 studied it in previously treated patients with metastatic melanoma.
ABI-007 is a small molecule therapeutic. Its specific molecular target has not been disclosed in the available clinical trial information. The drug is being investigated for its anti-cancer activity across multiple tumor types.
ABI-007 is also known as Abraxane, a formulation of paclitaxel bound to albumin. Clinical trials have used the name ABI-007 to refer to this drug, which has been studied in breast cancer, non-small cell lung cancer, and melanoma.